Literature DB >> 17303904

Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.

D Kandiloros1, A Eleftheriadou, T Chalastras, L Kyriou, I Yiotakis, E Ferekidis.   

Abstract

OBJECTIVE: The identification of a reliable circulating tumor marker in squamous cell carcinoma of the head and neck (SCCHN) could assist in diagnosis and monitoring response to therapy. AIM: The aim of this study was to investigate the effectiveness of the serum tumor markers CYFRA 21-1, TPA-M, SCCA, and CEA. STUDY
DESIGN: Serum levels of CYFRA 21-1, TPA-M, SCCA, and CEA were measured in 136 patients with a histologically proven SCCHN before and after treatment and in 125 healthy subjects, as controls. We evaluated the sensitivity and specificity of these tumor markers and to correlate their levels with tumor staging, grading, or performance status.
RESULTS: The study showed that none of the above markers presented satisfactory specificity and sensitivity in early diagnosis. In comparison with the other markers, TPA-M was the most effective of all markers and indicated a positive correlation with the grade of differentiation and nodal status. A remarkable correlation between high levels of TPA-M and CYFRA 21-1 in advanced stages (III, IV) of cancer has been shown.
CONCLUSIONS: All the tumor markers that were studied have significant limitations in the early diagnosis of cancer, but TPA-M and CYFRA 21-1 may have a role in monitoring the success of therapy and follow up of patients with SCCHN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17303904     DOI: 10.1385/MO:23:4:463

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  32 in total

Review 1.  Circulating markers in squamous cell carcinoma of the head and neck: a review.

Authors:  C H Rassekh; J T Johnson; D E Eibling
Journal:  Eur J Cancer B Oral Oncol       Date:  1994-01

2.  Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.

Authors:  Chih-Jaan Tai; Feng-Yuan Liu; Ji-An Liang; Shih-Neng Yang; Ming-Hsui Tsai; Cbia-Hung Kao
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

3.  A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen.

Authors:  T C Yen; W Y Lin; C H Kao; K Y Cheng; S J Wang
Journal:  Clin Otolaryngol Allied Sci       Date:  1998-02

Review 4.  Epidemiology and risk factors for head and neck cancer.

Authors:  M R Spitz
Journal:  Semin Oncol       Date:  1994-06       Impact factor: 4.929

5.  Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratins 8, 18 and 19. Second report of the TD5 workshop.

Authors:  M Nap; T van Wel; C Andrés; L Bellanger; H Bodenmüller; H Bonfrer; J Brundell; R Einarsson; A Erlandsson; A Johansson; J F Leca; T Meier; P Seguin; A Sjödin; T Stigbrand; B E Sundström; A van Dalen; E Wiebelhaus; B Wiklund; J Hilgers
Journal:  Tumour Biol       Date:  2001 Jan-Feb

6.  Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.

Authors:  A Banal; K Hacene; E Berthelot-Ruff; E Mahé; X Fontana; M F Pichon
Journal:  Tumour Biol       Date:  2001 Jan-Feb

7.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

8.  Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas.

Authors:  A Becciolini; S Porciani; A Lanini; M Tommasi; P Olmi; A Chiavacci
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

9.  Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck.

Authors:  I Doweck; M Barak; E Greenberg; N Uri; J Kellner; M Lurie; N Gruener
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1995-02

10.  [CEA studies in squamous cell carcinomas of the head and neck].

Authors:  M Schröder; T Meyer
Journal:  HNO       Date:  1986-08       Impact factor: 1.284

View more
  4 in total

1.  Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis.

Authors:  Lihui Liu; Wenji Xie; Pei Xue; Zixuan Wei; Xiao Liang; Nianyong Chen
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

2.  Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.

Authors:  Sumitaka Hagiwara; Eiichi Sasaki; Yasuhisa Hasegawa; Hidenori Suzuki; Daisuke Nishikawa; Shintaro Beppu; Hoshino Terada; Michi Sawabe; Masahide Takahashi; Nobuhiro Hanai
Journal:  Cancer Med       Date:  2021-02-09       Impact factor: 4.452

3.  Salivary Scca1, Scca2 and Trop2 in Oral Cancer Patients-A Cross-Sectional Pilot Study.

Authors:  Ivana Karmelić; Ivan Salarić; Ksenija Baždarić; Marko Rožman; Ivan Zajc; Marinka Mravak-Stipetić; Ivona Bago; Davor Brajdić; Jasna Lovrić; Darko Macan
Journal:  Dent J (Basel)       Date:  2022-04-15

Review 4.  Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.

Authors:  Andrea Santarelli; Marco Mascitti; Lucio Lo Russo; Davide Sartini; Giuseppe Troiano; Monica Emanuelli; Lorenzo Lo Muzio
Journal:  Int J Mol Sci       Date:  2018-03-24       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.